СПИСОК ЛИТЕРАТУРЫ

1. Delvigne A., Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; 8(6):559-77.

2. Корсак B.C. Регистр Центров ВРТ России. Отчет за 2010 год. Проблемы репродукции. 2013; 19(1):7-16.

3. Royal College of Obstetricians and Gynaecologists. The Management of Ovarian Hyperstimulation Syndrome. 2006; http://www.rcog.org.uk/files/rcog-corp/GTG5_230611.pdf.

4. Delvigne A., Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003; 9(1):77-96.

5. Назаренко Т.А., Корнеева И.Е., Сароян Т.Т., Веряева Н.А. Спонтанный синдром гиперстимуляции яичников при одноплодной беременности. Проблемы репродукции. 2009; 15(1):71-75.

6. Delbaere A., Smits G., De Leener A., Costagliola S., Vassart G. Understanding ovarian hyperstimulation syndrome. Endocrine. 2005; 26(3):285-90.

7. Binder H., Dittrich R., Einhaus F., Krieg J., Muller A., Strauss R., et al. Update on ovarian hyperstimulation syndrome: Part 1 - Incidence and pathogenesis. Int J Fertil Womens Med. 2007; 52(1):11-26.

8. Avecillas J.F., Falcone Т., Arroliga A.C. Ovarian hyperstimulation syndrome. Crit Care Clin. 2004; 20(4):679-95, ix.

9. Budev M.M., Arroliga A.C, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med. 2005; 33 (10 Suppl):S301-6.

10. Корнеева И.Е., Сухих Г.Т., Сароян Т.Т. Иммунные аспекты патофизиологии синдрома гиперстимуляции яичников. Акушерство и гинекология. 2009; 3:3-6.

11. Agrawal R., Tan S.L., Wild S., Sladkevicius P., Engmann L., Payne N., et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999; 71(2):287-93.

12. Vasseur C., Rodien P., Beau I., Desroches A., Gerard C., de Poncheville L., et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med. 2003; 349 (8):753-9.

13. Daelemans C., Smits G., de Maertelaer V., Costagliola S., Englert Y., Vassart G., et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab. 2004; 89(12):6310-5.

14. Корнеева И.Е., Камилова Д.П., Волков Н.И., Ковалев В.Ф. Случай тяжелого течения синдрома гиперстимуляции яичников. Проблемы репродукции. 1999; 5(2):65-66.

15. Сароян Т.Т., Корнеева И.Е., Перминова С.Г., Ибрагимова М.Х. Функция щитовидной железы у женщин с индуцированной беременностью на фоне синдрома гиперстимуляции яичников. Проблемы репродукции. 2008; 14(2):68-72.

16. Practice Committee of the American Society for Reproductive M. Ovarian hyperstimulation syndrome. Fertil Steril. 2006; 86 (5 Suppl 1):S178-83.

17. Ставничук А.В. Профилактика тромбоэмболических осложнений у женщин с синдромом гиперстимуляции яичников: Автореф. дис., канд. мед. наук. М.; 2009. 24 с.

18. Abramov Y., Elchalal U., Schenker J.G. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 1999; 71(4):645-51.

19. Beji О., Brahmi N., Thabet H., Mokline A., Abidi N., Blel Y., et al. Compressive pleural effusion after ovarian hyperstimulation syndrome-a case report and review. Fertil Steril. 2008; 89(6):1826 e1-3.

20. Abramov Y., Elchalal U., Schenker J.G. Febrile morbidity in severe and critical ovarian hyperstimulation syndrome: a multicentre study. Hum Reprod. 1998; 13(11):3128-31.

21. Boldt J., Ducke M., Kumle В., Papsdorf M., Zurmeyer E.L. Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery. Intensive Care Med. 2004; 30(3):416-22.

22. Nelson S.M. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thromb Res. 2013; 131 Suppl 1:S1-3.

23. Stolzel K., Jovanovic S., Albers A.E. [Jugular vein thrombosis caused by hypercoagulability following in-vitro fertilization-activated protein С resistance and immobilization]. HNO. 2013; 61(3):250-5.

24. Chan W.S. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009; 21(3):207-18.

25. Carlotti A.P., Carvalho W.B. Abdominal compartment syndrome: A review. Pediatr Crit Care Med. 2009; 10(1):115-20.

26. Selgas R., Del Peso G., Bajo M.A. Intra-abdominal hypertension favors ascites. Perit Dial Int. 2010; 30(2):156-7.

27. Light R.W. The undiagnosed pleural effusion. Clinics in Chest Medicine. 2006; 27(2):309-+.

28. Harman P.K., Kron I.L., McLachlan H.D., Freedlender A.E., Nolan S.P. Elevated intra-abdominal pressure and renal function. Ann Surg. 1982; 196(5):594-7.

29. Abramov Y., Naparstek Y., Elchalal U., Lewin A., Schechter E., Schenker J.G. Plasma immunoglobulins in patients with severe ovarian hyperstimulation syndrome. Fertil Steril. 1999; 71(1):102-5.

30. Сароян Т.Т. Особенности течения беременности у женщин с тяжелой формой синдрома гиперстимуляции яичников: Автореф. дис., канд. мед. наук. М.; 2009. 25 с.

31. Кетиладзе Т.М. Прогностическое значение онкомаркера СА-125 при синдроме гиперстимуляции яичников: Автореф. дис., канд. мед. наук. М.; 1999. 24 с.

32. Корнеева И.Е., Веряева Н.А., Анкирская А.С., Королева Т.Е. Оценка роли микробного фактора и диагностической ценности теста на прокальцитонин при синдроме гиперстимуляции яичников. Проблемы репродукции. 2009; 15(3):35-39.

33. Корнеева И.Е., Веряева Н.А. Комплексная терапия при синдроме гиперстимуляции яичников. Врач. 2006; 9:54-56.

34. Gamzu R., Almog В., Levin Y., Avni A., Lessing J.B., Baram A. Efficacy of hydroxyethyl starch and haemaccel for the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril. 2002; 77(6):1302-3.

35. Feng X., Yan W., Liu X., Duan M., Zhang X., Xu J. Effects of hydroxyethyl starch 130/0.4 on pulmonary capillary leakage and cytokines production and NF-kappaB activation in CLP-induced sepsis in rats. J Surg Res. 2006; 135(1):129-36.

36. Van der Linden P.J., De Hert S.G., Deraedt D., Cromheecke S., De Decker K., De Paep R., et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg. 2005; 101(3):629-34, table of contents.

37. Hoffmann J.N., Vollmar В., Laschke M.W., Inthorn D., Schildberg F.W., Menger M.D. Hydroxyethyl starch (130 kD), but not crystalloid volume support, improves microcirculation during normotensive endotoxemia. Anesthesiology. 2002; 97(2):460-70.

38. Корнеева И.Е., Назаренко Т.А., Аксененко А.А., Соколова М.Ю. Нарушение функции печени у пациентки с синдромом гиперстимуляции яичников. Проблемы репродукции. 2009; 15(3):70-73.

39. Bellver J., Munoz E.A., Ballesteros A., Soares S.R., Bosch E., Simon C., et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod. 2003; 18(11):2283-8.

40. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998; 317(7153):235-40.

41. British Consensus Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients. Anaesthesia. 2009; 64(3):235-238.

42. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod. 1992; 7(2):180-3.

43. Bellomo R., Chapman M., Finfer S., Hickling K., Myburgh J., Belessis A., et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Lancet. 2000; 356(9248):2139-43.

44. Корнеева И.Е., Фанченко Н.Д., Иванова А.В., Иванец Т.Ю. Определение фактора Виллебранда с целью прогнозирования тяжести синдрома гиперстимуляции яичников. Материалы XIV международной конференции Российской Ассоциации Репродукции Человека "Репродуктивные технологии сегодня и завтра". Москва, 26 - 28 сентября 2004 г. М.; 2004:93-94.

45. Boldt J., Haisch G., Suttner S., Kumle В., Schellhaass A. Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend) on measures of coagulation. Br J Anaesth. 2002; 89(5):722-8.

46. Ickx B.E., Bepperling F., Melot C., Schulman C., Van der Linden P.J. Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution. Br J Anaesth. 2003; 91(2):196-202.

47. Сароян Т.Т., Корнеева И.Е. Тактика ведения индуцированной беременности, наступившей на фоне тяжелого течения синдрома гиперстимуляции яичников. Акушерство и гинекология. 2011; 8:107-11.

48. Корнеева И.Е., Камилова Д.П., Фанченко Н.Д., Иванец Т.Ю., Леонов Б.В. Профилактика тромбоэмболических осложнений у пациенток с синдромом гиперстимуляции яичников. Проблемы репродукции. 2002; 8(2):30-33.

49. Abuzeid M.I., Nassar Z., Massaad Z., Weiss M., Ashraf M., Fakih M. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod. 2003; 18(2):370-3.

50. Ferraretti A.P., Goossens V., de Mouzon J., Bhattacharya S., Castilla J.A., Korsak V., et al. Assisted reproductive technology in Europe, 2008: results generated from European registers by ESHRE. Hum Reprod. 2012; 27(9):2571-84.

51. Humaidan P., Quartarolo J., Papanikolaou E.G. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010; 94(2):389-400.

52. Peng C., Fan N.C., Ligier M., Vaananen J., Leung P.C. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology. 1994; 135(5):1740-6.

53. Weiss J.M., Oltmanns K., Gurke E.M., Polack S., Eick F., Felberbaum R., et al. Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. Eur J Endocrinol. 2001; 144(6):677-85.

54. Asimakopoulos В., Nikolettos N., Nehls В., Diedrich K., Al-Hasani S., Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril. 2006; 86(3):636-41.

55. Youssef M.A., Al-Inany H.G., Evers J.L., Aboulghar M. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2011(2):CD001302.

56. Youssef M.A., Van der Veen F., Al-Inany H.G., Griesinger G., Mochtar M.H., Aboulfoutouh I., et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011(1):CD008046.

57. Humaidan P. Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertil Steril. 2012; 97(3):529-30.

58. Shapiro B.S., Daneshmand S.T., Garner F.C., Aguirre M, Hudson С Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril. 2011; 95(8):2715-7.

59. Radesic В., Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod. 2011; 26(12):3437-42.

60. Youssef M.A., van Wely M., Hassan M.A., Al-Inany H.G., Mochtar M., Khattab S., et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010; 16(5):459-66.

61. Acevedo В., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006; 86(6):1682-7.

62. Melo M., Busso C.E., Bellver J., Alama P., Garrido N., Meseguer M., et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009; 19(4):486-92.

63. Manzanares M.A., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril. 2010; 93(4):1215-9.

64. Arce J.C., Klein B.M., La Marca A. The rate of high ovarian response in women identified at risk by a highserum АМН level is influenced by the type of gonadotropin Gynecol Endocrinol. 2014 Jun; 30(6):444-50.

65. Devroey P., Pellicer A., Nyboe Andersen A., Arce J.C.; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012 Mar; 97(3):561-71.